By Scientia Professor Vlado Perkovic

Journal articles

Beal B; Buizen L; Yeung EK; Heath L; Houston L; Cherney DZI; Jardine M; Pollock C; Arnott C; Kotwal SS; Heerspink HJL; Perkovic V; Neuen BL, 2025, 'Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial', Nephrology Dialysis Transplantation, 40, pp. 1727 - 1735, http://dx.doi.org/10.1093/ndt/gfaf044

Oshima M; Buizen L; Jongs N; Levin A; Chertow GM; Wheeler DC; Heerspink HJL; Arnott C; Jardine MJ; Mahaffey KW; Pollock C; Herrington WG; Perkovic V; Neuen BL, 2025, 'Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials', Clinical Journal of the American Society of Nephrology, 20, pp. 1206 - 1214, http://dx.doi.org/10.2215/CJN.0000000771

Mazhar F; Fu EL; Faucon AL; Hjemdahl P; Mathisen J; Muhammad IF; Plunde O; Perkovic V; Tuttle KR; Carrero JJ, 2025, 'Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease', American Journal of Kidney Diseases, 86, pp. 314 - 323.e1, http://dx.doi.org/10.1053/j.ajkd.2025.04.011

Jeyaruban A; Bose B; Lee VW; Jardine M; Mallawaarachchi A; Ritchie A; Wong MG; Makris A; Badve SV; Siriwardana A; Yong K; Perkovic V; Kotwal S, 2025, 'Glomerular disease registry and biobank: design and baseline results', Internal Medicine Journal, 55, pp. 1301 - 1307, http://dx.doi.org/10.1111/imj.70056

Chatur S; Vaduganathan M; Fletcher RA; Perkovic V; Heerspink H; Arnott C; Pollock C; Mahaffey KW; Neal B; Jardine M; Solomon SD; Neuen BL, 2025, 'Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials', European Journal of Heart Failure, 27, pp. 994 - 1002, http://dx.doi.org/10.1002/ejhf.3586

Kim D; Neuen BL; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Fletcher RA; Billot L; Perkovic V; Zhang H; Wong MG, 2025, 'Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR', Kidney International Reports, 10, pp. 1886 - 1895, http://dx.doi.org/10.1016/j.ekir.2025.03.008

Nguyen TN; Yu J; Perkovic V; Jardine M; Mahaffey KW; Chow CK; Arnott C; Lindley RI, 2025, 'The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials', Journal of the American Geriatrics Society, 73, pp. 1787 - 1796, http://dx.doi.org/10.1111/jgs.19444

Barratt J; Perkovic V; Rizk DV, 2025, 'Alternative Complement Pathway, Iptacopan, and IgA Nephropathy: The authors reply', New England Journal of Medicine, 392, pp. 1976, http://dx.doi.org/10.1056/NEJMc2503117

Lee MMY; Sattar N; Pop-Busui R; Deanfield J; Emerson SS; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter NR; Badve SV; Pratley RE; Perkovic V; Buse JB; McGuire DK, 2025, 'Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials', Diabetes Care, 48, pp. 846 - 859, http://dx.doi.org/10.2337/dc25-0241

Greene T; Collier W; Haaland B; Zhang C; Badve SV; Caravaca-Fontán F; Del Vecchio L; Floege J; Hannedouche T; Imai E; Jafar TH; Lewis JB; Li PKT; Locatelli F; Maes BD; Neuen BL; Perrone RD; Schena FP; Toto R; Wanner C; Woodward M; Van Zuilen A; Heerspink HJL; Inker LA; Estacio RO; Hanratty R; Chalmers J; Parving HH; Appel GB; Canetta P; Brenner BM; Barrett B; Neal B; Mahafey KW; Neuen B; Johnson D; Perkovic V; Mahaffey KW; Jardine M; Fervenza F; Von Eynatten M; Goicoechea M; Verde E; Verdalles U; Arroyo D; Chapman A; Torres V; Yu A; Brosnahan G; Kam-Tao Li P; Chow KM; Szeto CC; Leung CB; Xie D; Hou FF; Dwyer J; Pohl M; Raz I; Hunsicker L; Becker GJ; Ihle BU; Kincaid-Smith PS; Kamper A; Katafuchi R; Vanacker A; Malfait T; Maschio G; Van Kruijsdijk R; Vernooij RWM; Kobayashi F; Makino H; Chan JCN; Passerini P; Andrulli S; Pozzi C; Casartelli D; Praga M; Trujillo H; Cavero T; Sevillano A; Ruggenenti P; Perna A; Carrara F; Gherardi G; Keane WF; Manno C; Haynes R; Herrington WG; Baigent C; Landray M; Rauen T; Seikrit C; Wied S; De Zeeuw D; De Jong PE; Saddelli M; Zucchelli P, 2025, 'Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression', Clinical Journal of the American Society of Nephrology, 20, pp. 632 - 641, http://dx.doi.org/10.2215/CJN.0000000662

Koshino A; Heerspink HJL; Jongs N; Badve SV; Arnott C; Neal B; Jardine M; Mahaffey KW; Pollock C; Perkovic V; Hansen MK; Bakker SJL; Wada T; Neuen BL, 2025, 'Canagliflozin and iron metabolism in the CREDENCE trial', Nephrology Dialysis Transplantation, 40, pp. 696 - 706, http://dx.doi.org/10.1093/ndt/gfae198

Siriwardana A; Buizen L; Jun M; Kotwal S; Arnott C; Jardine MJ; Levin A; Heerspink HJL; Charytan DM; Pollock C; Perkovic V; Neuen BL, 2025, 'Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 27, pp. 1972 - 1979, http://dx.doi.org/10.1111/dom.16190

Chan B; Varghese A; Badve SV; Pecoits-Filho R; Guedes M; Arnott C; Kozor R; O'Lone E; Jun M; Kotwal S; Block GA; Chertow GM; Solomon SD; Vaduganathan M; Perkovic V; Neuen BL, 2025, 'Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD', Kidney International Reports, 10, pp. 1037 - 1049, http://dx.doi.org/10.1016/j.ekir.2025.01.029

Mahaffey KW; Tuttle KR; Arici M; Baeres FMM; Bakris G; Charytan DM; Cherney DZI; Chernin G; Correa-Rotter R; Gumprecht J; Idorn T; Pugliese G; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann JFE; Perkovic V; Pratley R, 2025, 'Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial', European Heart Journal, 46, pp. 1096 - 1108, http://dx.doi.org/10.1093/eurheartj/ehae613

Siriwardana A; Smyth B; Jardine M, 2025, 'Waiver of informed consent in clinical research: a summary of contemporary guidelines and a resource for researchers', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-091896

Webster ER; Perkovic A; Neuen BL; Tuttle KR; Perkovic V, 2025, 'Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials', Clinical Kidney Journal, 18, http://dx.doi.org/10.1093/ckj/sfaf001

Perkovic V; Barratt J; Rovin B; Kashihara N; Maes B; Zhang H; Trimarchi H; Kollins D; Papachristofi O; Jacinto-Sanders S; Merkel T; Guerard N; Renfurm R; Hach T; Rizk DV, 2025, 'Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy', New England Journal of Medicine, 392, pp. 531 - 543, http://dx.doi.org/10.1056/NEJMoa2410316

Heerspink HJL; Agarwal R; Bakris GL; Cherney DZI; Lam CSP; Neuen BL; Sarafidis PA; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen P; Perkovic V; Bittar J; Zaidman CJ; Cluigt N; Hominal M; Aguerre P; Halac F; Gelersztein E; Arriola M; Maldonado R; Chahin M; Packham D; Lee D; Pedagogos E; Foote C; Badve S; Hawley C; Chen J; Gray N; Speeckaert M; Labriola L; Doubel P; Maes B; Claes K; Dubois B; Dimitrova I; Vutova T; Ilchev S; Stamova S; Ivanova Y; Vasileva A; Chen X; Tang S; Xu X; Liu B; He W; He Y; Liu F; Wang C; Chen L; Niu J; Wang D; Luo P; Xia Y; Jiang G; Luo Q; Wang F; Chen M; Lin H; Yan R; Li Y; Chen Q; Dong J; Xiong F; Long H; Cheng H; Li Y; Du J; Liu F; Chen Q; Lu W; Chen C; Wang J; Liu L; Yang M; Long G; Shi Y; Li W; Yang X; Yang A; Li J; Meng X; Prazny M; Hornova L; Bucek P; Majernikova M; Wirth J; Rehorova J; Hornum M; Bech J; Lindhardt M; Hansen D; Mortensen L; Juhl C; Boletis I; Papadopoulou D, 2025, 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial', Nephrology Dialysis Transplantation, 40, pp. 308 - 319, http://dx.doi.org/10.1093/ndt/gfae132

Kotwal SS; Perkovic V, 2025, 'Effects of Semaglutide on CKD in Patients With Type 2 Diabetes', Kidney International Reports, 10, pp. 287 - 290, http://dx.doi.org/10.1016/j.ekir.2024.11.1365

Badve SV; Bilal A; Lee MMY; Sattar N; Gerstein HC; Ruff CT; McMurray JJV; Rossing P; Bakris G; Mahaffey KW; Mann JFE; Colhoun HM; Tuttle KR; Pratley RE; Perkovic V, 2025, 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials', Lancet Diabetes and Endocrinology, 13, pp. 15 - 28, http://dx.doi.org/10.1016/S2213-8587(24)00271-7

Talbot B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Kaur N; Knight J, 2025, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, 45, pp. 52 - 56, http://dx.doi.org/10.1177/08968608231209850

Barratt J; Perkovic V; Sprangers B; Rovin B; Kashihara N; Maes BD; Zhang H; Trimarchi H; Grioni A; Applegate D; Hach T; Merkel T; Desai MM; Renfurm R; Rizk DV, 2025, 'Biomarker Insights from the Phase 3 APPLAUSE-IgAN Study: Iptacopan's Proteomic Signature in IgAN', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025k8sb4c4c

Enríquez AJ; Mahaffey KW; Tuttle K; Baeres FMM; Bakris G; Idorn T; Perkovic V; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann J; Pratley R, 2025, 'CO-025. RESULTADOS CARDIOVASCULARES CON SEMAGLUTIDA EN FUNCIÓN DEL ESTADO BASAL DE LA ENFERMEDAD RENAL CRÓNICA EN PARTICIPANTES CON DIABETES TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: RESULTADOS DEL ENSAYO FLOW', Endocrinología, Diabetes y Nutrición, 72, pp. 15 - 15, http://dx.doi.org/10.1016/s2530-0164(25)00132-6

Soveri I; Mann JF; Pratley RE; Schmieder RE; Cherney D; MacIsaac RJ; Rossing P; Mahaffey KW; L S; Bellary S; Perkovic V; Lim SK; Gumprecht J; Belmar N; Bosch-Traberg H; Rasmussen S; Tuttle KR; Charytan DM, 2025, 'Discordance Between Cystatin C-Based eGFR and Creatinine-Based eGFR and Cardiovascular Risk in the FLOW Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025jg5nr2bm

Friedman AN; Pratley RE; Tuttle KR; Mehanna S; Swift C; Rasmussen S; Rossing P; Perkovic V; Mahaffey KW; Basile JN, 2025, 'Effect of Semaglutide on Hemoglobin A1c and Body Weight Change by CKD Stage: Post Hoc Analysis from the FLOW Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025fr6fq33q

Mann JF; Badve S; Baeres FMM; Belmar N; Brown-Frandsen KS; Buse J; Colhoun H; Deanfield J; Engelmann MDM; Hovingh K; Idorn T; Lincoff AM; Lingvay I; Mahaffey KW; McGuire DK; Pratley RE; Rasmussen S; Rossing P; Sattar N; Tuttle KR; Perkovic V, 2025, 'Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025vd9epqq7

Zhang H; Perkovic V; Barratt J; Rizk DV; Rovin B; Trimarchi H; Maes BD; Merkel T; Desai MM; Ansari S; Hach T; Renfurm R; Kashihara N, 2025, 'Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025bmx8dwvd

Lv J; Liu L-J; Wang W; Zhang J; Mao W; Zuraw Q; Perkovic V; Fang J; Zhang H, 2025, 'Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study', Journal of the American Society of Nephrology, 36, pp. 10.1681/asn.2025n4b0qfm4, http://dx.doi.org/10.1681/asn.2025n4b0qfm4

L S; Arici M; Bax WA; Busch RS; Correa-Rotter R; Gorriz JL; Gumprecht J; Idorn T; Mahaffey KW; Mann JF; Mayrdorfer M; Baastrup Nordsborg R; Pratley RE; Pugliese G; Rasmussen DGK; Rossing P; Tangri N; Tuttle KR; Perkovic V, 2025, 'FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.20257qtjpx6z

Kotwal SS; Jeyaruban AS; Bose B; Lee VWS; Jardine M; Mallawaarachchi A; Ritchie AG; Wong MG; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'Glomerular Disease Registry and Biobank: Baseline and Follow-Up Results', Journal of the American Society of Nephrology, 36, pp. 10.1681/asn.2025a2e9nynn, http://dx.doi.org/10.1681/asn.2025a2e9nynn

Neuen BL; Fletcher RA; Perkovic V; Heerspink HJL, 2025, 'Impact of Glomerular Filtration Rate and Albuminuria on the Effects of SGLT2 Inhibitors on Kidney Outcomes', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025bs338s8x

Mende CW; Campos C; Pratley RE; Tuttle KR; Mehanna S; Swift C; Rasmussen S; Rossing P; Perkovic V; Mahaffey KW, 2025, 'Kidney, Cardiovascular, and Death Outcomes with Semaglutide Treatment Among Two Race and Two Ethnic Groups: Post Hoc Analysis from the FLOW Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025nztajebj

Wong MG; Lv J; Bao Y; Anderson RJ; Kim D; Shan S; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Perkovic V; Zhang H, 2025, 'Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study', Journal of the American Society of Nephrology, 36, pp. 10.1681/asn.20259xwps6re, http://dx.doi.org/10.1681/asn.20259xwps6re

Varas IJ; Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann J; Bakris G; Baeres FM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R; Committees and Investigators FT, 2025, 'P-190. ENSAYO FLOW: EFECTO DE SEMAGLUTIDA EN PERSONAS CON ENFERMEDAD RENAL CRÓNICA Y DIABETES TIPO 2', Endocrinología Diabetes y Nutrición, 72, pp. 76 - 77, http://dx.doi.org/10.1016/s2530-0164(25)00253-8

Heerspink HJL; Pecoits-Filho R; Ambery PD; Eryd SA; Lesén E; Nam Y-S; Thuresson M; Perkovic V, 2025, 'Risk of CKD Progression in a Real-World Population Eligible for the ZENITH-High Proteinuria Trial', Journal of the American Society of Nephrology, 36, pp. 10.1681/asn.2025kp13gres, http://dx.doi.org/10.1681/asn.2025kp13gres

Perkovic V; Barratt J; Lafayette RA; Liew A; Suzuki Y; Carroll K; Cheung CK; Tesar V; Trimarchi H; Wong MG; Zhang H; Xia J; Fajardo C; Shah LN; Hafkin J; Rizk DV, 2025, 'Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses', Journal of the American Society of Nephrology, 36, pp. 10.1681/asn.20252v4ch0af, http://dx.doi.org/10.1681/asn.20252v4ch0af

Odler B; Riedl R; Geetha D; Szpirt WM; Hawley C; Uchida L; Wallace ZS; Walters G; Muso E; Tesar V; Pusey CD; Little MA; Merkel PA; Walsh M; Jayne DRW; Kronbichler A; Paizis K; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Vilayur E; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Reidlinger D; AliciaMorrish ; Badve SV; Pascoe E; Paul-Brent P-A; Robison L; Valks A; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Walsh M; Khalidi N; Cox G; Mazzetti A; Robins D; Wald R; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Chantrel F; Vanhille P; Quémeneur T; Carron P-L; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M; Aniort J; Lavigne C; Augusto JF; Chauveau D; Guitard J; Huart A; Ribes D; Gatault P; Becmeur C; Muller S; Betz V; Klein A; Blaison G; Seror R; Francois H; Mariette X; Aubrun A; Coustet B; Palazzo E; Ottaviani S; Goulenok T; Daugas E; Dieudé P; Papo T; Lebas C; Lionet A; Guillevin L; Mouthon L; Puéchal X; Jourde-Chiche N; Ruivard M; Karras A; Limal N; Kofman T; Le Quellec A; Maurier F; Gibelin A; Parrot A; Bachmeyer C; Gombert B; Nouvier M; Lega J-C; Fain O; Andrès E; Cottet R; Gregorini G; Jeannin G; Possenti S; Buzio C; Vaglio A; Oliva E; Makino H; Muso E; Endo T; Kakita H; Suzuki H; Handa T; Kang Y; Ariyasu Y; Tsukamoto T; Endo S; Miyata H; Yamada H; Ito-Ihara T; Uchida S; Kono H; Fujigaki Y; Kikuchi H; Nanki T; Kato H; Okamoto A; Asako K; Suzuki K; Hamano Y; Yamagata K; Usui J; Fujimoto S; Sato Y; Kikuchi M; Flores-Suárez LF; Sánchez-Guerrero SA; Collins M; Schollum J; de Zoysa J; Quincy V; Sizeland P; Aasarod K; Solbu M; Bruun TJ; Koldingsnes W; Wludarczyk A; Nowak I; Gorka J; Sznajd J; Padjas A; Jankowski M; Widawska A; Szczeklik W; Ballarin J; Bruchfeld A; Efvergren M; Eriksson P; Westman K; Selga D; Heijl C; Ohlsson S; Segelmark M; Basu N; Kidder D; Fluck N; Jayne DRW; Smith R; Wilcocks L; McClure M; Jones R; Trivedi S; Gopaluni S; Brettell E; Crump P; Feilbach A; Hewitt C; Hilken N; Howman A; Hughes T; Ives N; Jarrett H; Mehta S; Record R; Ryan G; Sidile C; Wheatley K; Sheerin ; Brown A; Baines LA; Lordan J; Pusey C; Tanna A; McAdoo S; Levy J; Griffith M; Klebe B; Doulton T; Warwick G; Burton J; Barratt J; Topham P; Baines R; Brunskill N; Al-Jayyousi R; Hamilton P; Patel M; Mitra S; Brown N; Sharples E; Luqmani R; Harper L; Rhodes B; Chanouzas D; Morgan M; Hewins P; Floßmann O; Bhandary N; Foxton J; Jones L; King J; Smyth L; D’Souza R; Haigh R; Hough M; Smyth L; Haigh R; Hough M; Salama A; Burns A; Little M; Dhaun N; Dhaygude A; Basnayake K; Iggo N; Jones D; Oliveira D; MacPhee IAM; Dunn E; Lewington AJP; Fan SL; Rajakariar R; Yaqoob M; Short A; Geddes C; Mackinnon B; Jardine AG; Monach P; Merkel PA; Amudala N; Quillen K; Weisman M; Wallace D; Forbess L; Venuturupalli S; Langford C; Hajj-Ali R; Koo A; Hoffman G; Specks U; Keogh K; Ytterberg S; Winters J; Warrington K; Cartin-Ceba R; Peikert T; Fervenza F; Baqir M; Nachman P; Detwiler R; Mottl A; Derebail V; McGregor J; Merkel PA; Sreih A; Rhee R; McAlear C; Aqui N; Moreland L; Kiss J; Liang K; Mohan N; Balogun R; Li T; Brasington R, 2025, 'The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial', Kidney International, 107, pp. 558 - 567, http://dx.doi.org/10.1016/j.kint.2024.11.029

Kotwal S; Jeyaruban A; Bose B; Lee V; Jardine M; MALLAWARCHCHI A; Ritchie A; Wong M-G; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'WCN25-1567 Glomerular disease registry and Biobank (GRIT)– design and baseline results', Kidney International Reports, 10, pp. s196 - s197, http://dx.doi.org/10.1016/j.ekir.2024.11.382

Kotwal S; Perkovic V; Jardine M; Vart P; Wheeler D; de Boer I; Zhang H; Hou FF; Sugawara Y; De Nicola L; Gorriz J; Heerspink H, 2025, 'WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK', Kidney International Reports, 10, pp. S287 - S288, http://dx.doi.org/10.1016/j.ekir.2024.11.535

Tuttle K; Arici M; Arslan EG; Bellary S; Idorn T; Ji L; Kamenov Z; Kashihara N; Mann J; Mahaffey K; Perkovic V; Rasmussen S; Rossing P; Schytz PA; Sreenivasamurthy L; Pratley R, 2025, 'WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial', Kidney International Reports, 10, pp. S770 - S770, http://dx.doi.org/10.1016/j.ekir.2024.11.1358

Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', Kidney International Reports, 10, pp. s158 - s159, http://dx.doi.org/10.1016/j.ekir.2024.11.328

Rizk D; Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY (vol 10, pg S158, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2892 - 2892

Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.11.358

Perkovic V; Rizk D; Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY (vol 10, pg S177, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R; Perkovic V, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS', Kidney International Reports, 10, pp. S183 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.362

Perkovic V; Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS (vol 10, pg S183, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S184 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.363

Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY( vol 10, pg S184 , 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Perkovic V; Tuttle K; Sattar N; Lincoff AM; Navar AM; Marx N; Hvelplund A; Baeres FMM; Engelmann MD; Hovingh GK; Ridker PM, 2025, 'WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE', Kidney International Reports, 10, pp. s767 - s768, http://dx.doi.org/10.1016/j.ekir.2024.11.1354

Kotwal SS; Perkovic V; Jardine MJ; Kim D; Shah NA; Lin E; Coggan S; Billot L; Vart P; Wheeler DC; De Boer IH; Zhang H; Hou FF; Sugawara Y; Marion J; Lewis RJ; Berry LR; McGlothlin A; Jha V; De Nicola L; Gorriz JL; Heerspink HJL, 2024, 'The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol', JAMA Network Open, 7, http://dx.doi.org/10.1001/jamanetworkopen.2024.49998

Back to profile page